Scintigraphic Detection of Gastrointestinal Hemorrhage: Current Status

Robert J. Lull and George L. Morris
Letterman Army Medical Center, Presidio of San Francisco, California

This is the second in a series of four Continuing Education articles on imaging techniques. After studying this article the reader should be able to: 1) discuss why the detection of GI bleeding is clinically important; and 2) be aware of various imaging techniques and potential pitfalls.

Localization of the specific bleeding site in patients presenting with acute gastrointestinal (GI) hemorrhage remains a serious clinical problem. Alavi et al. (1) were the first to recognize a significant diagnostic role for scintigraphic imaging in localizing bleeding lesions. Their pioneering work, which was reported in 1977, stimulated extensive investigation to better define the proper role of scintigraphy in patients with GI hemorrhage. As a result, scintigraphy has emerged as the imaging modality of first choice for localizing bleeding sites in the lower GI tract. This paper is a selective review of the current status of radionuclide imaging in GI hemorrhage.

CLINICAL PERSPECTIVE

The clinical presentation, probable cause, and diagnostic evaluation of acute GI hemorrhage depend to a large extent on the location of the bleeding site. The GI tract is divided into two parts with the boundary being the ligament of Treitz at the junction of the duodenum and jejunum. The upper GI tract includes the esophagus, stomach, and duodenum. The lower GI tract includes all portions of the bowel distal to the ligament of Treitz (i.e., jejunum, ileum, and colon). Although scintigraphy may demonstrate bleeding sites in any portion of the GI tract, the major emphasis has been on the lower GI tract because of the clinical needs in this area.

Upper Gastrointestinal Hemorrhage

Bleeding above the ligament of Treitz is easily diagnosed and localized in 90% of patients by gastric aspiration and endoscopy. Major causes of bleeding in these patients are peptic ulcer, gastritis, esophagitis, esophageal varices, Mallory-Weiss syndrome, and tumors. Radionuclide imaging studies are generally not needed in upper GI bleeding because traditional endoscopic approaches are quite effective.

Lower Gastrointestinal Hemorrhage

The major causes of lower GI bleeding are diverticular disease, inflammatory bowel disease, tumors, and angiodysplasia (an acquired vascular malformation in the blood vessels of the bowel wall). In the pediatric and young adult population, Meckel's diverticulum is a common cause of bleeding. Sites of bleeding in the lower gastrointestinal tract, however, are often very difficult to localize not only during pre-operative diagnostic evaluation but also at surgery. This great diagnostic dilemma stems from both the long length and tortuosity of the lower GI tract as well as the typical intermittent pattern of blood loss in these patients. Another factor is the lack of a reliable clinical indicator capable of determining whether bleeding is active at any given time.

Patients with life threatening hemorrhaging who require emergency surgery will often become hypotensive and cease active bleeding before or during surgery, making it impossible to locate the specific origin of the bleeding during the operation. Thus, correct pre-operative localization of the bleeding site is essential for appropriate surgery. In the past, correct localization was impossible in many cases with traditional diagnostic approaches. In these cases, the surgeon was often forced to perform extensive blind bowel resections to control recurrent hemorrhage. As experience with scintigraphy increases, it seems to be evolving as clearly superior to other diagnostic modalities in pre-operative localization of lower GI bleeding sites (2,3).

Traditional Diagnostic Methods

Many of the traditional approaches listed in Table 1 have proven insensitive for detecting and localizing acute bleeding sites. Hematochezia, or passage of bloody stools, may continue for hours after cessation of active bleeding into the bowel
tracer is blood borne. The major difference is the rate of radio-
tracer clearance from the blood. Frequently cleared before onset of the next bleeding episode. Thus, angiography (vascular
angiography is used to screen for active bleeding before angiog-
raphy (4), or it is actually used to completely bypass diagnostic
angiography (5). Since angiography, however, requires active luminal bleeding and is often negative in intermittent bleeders or those with bleeding rates below 1.0 ml/min. In addition, angiography is uncomfort-
able, expensive, and has some risks. In many institutions, scin-
tigraphy has been the major diagnostic tool for localizing bleeding sites.

SCINTIGRAPHIC APPROACHES

Since the early work of Alavi and his colleagues in demon-
strating the theoretical basis and clinical superiority (over angi-
oigraphy) of scintigraphy using 99mTc-sulfur colloid, many in-
vestigators have reported success with 99mTc-red blood cells
(RBCs). Both techniques depend on scintigraphic visualization of active bleeding into the bowel lumen while the radio-
tracer is blood borne. The major difference is the rate of radio-
tracer clearance from the blood.

Evidence of 99mTc-RBC Superiority

Clinical experience reported by a number of investigators
(2,5-11) strongly supports the view that intermittent bleeding
is the dominant feature in most patients with lower GI hemor-
rhage (Fig. 1). Diagnostic agents with short blood-pool dura-
tion show lower diagnostic sensitivity because they are fre-
quently cleared before onset of the next bleeding episode.
Thus, angiography (vascular T1/2 < 30 sec) proved less sensi-
tive than 99mTc-sulfur colloid (vascular T1/2 = 3 min), which
was in turn shown much less sensitive than 99mTc-RBC (vas-
cular T1/2 > 24 hr) for demonstrating bleeding sites which
are so often intermittent. Clinical studies comparing 99mTc-
sulfur colloid and 99mTc-RBC performed in tandem all report
markedly better sensitivity for detecting bleeding with 99mTc-
RBC (5-11). The largest series, a multi-institutional prospec-
tive study of 100 patients, reported a sensitivity of 93% for
99mTc-RBC and only 12% for 99mTc-sulfur colloid in detecting
and localizing bleeding sites (8). Similar results were reported
for other tandem series (9-11). In light of such poor relative
sensitivity, 99mTc-sulfur colloid cannot be recommended for GI bleeding studies (Figs. 2 and 3). Using 99mTc-sulfur col-
loid and 99mTc-RBC in tandem may offer no diagnostic advantage over the use of 99mTc-RBC alone. Fur-
thermore, 99mTc-sulfur colloid adds radiation exposure and
causes significant background interference in the liver and spleen regions that may obscure a bleeding site on the sub-
sequent 99mTc-RBC study.

Role of the Meckel’s Scan

The [99mTc]pertechnetate Meckel’s scan differs fundamen-
tally from other scintigraphic bleeding studies in that it does
not demonstrate active bleeding, but rather shows the ectopic
gastric mucosa usually present in bleeding Meckel’s diver-


table}{Traditional Diagnostic Methods}{Stool: color, frequency, and guaiac test
Supine-Erect: blood pressure and pulse
Hematocrit and Hemoglobin
Proctoscopy and Colonoscopy
Barium Studies
Angiography

TABLE 1. Traditional Diagnostic Methods

<table>
<thead>
<tr>
<th>Diagnostic Method</th>
<th>Sensitivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stool: color, frequency,</td>
<td>Low</td>
</tr>
<tr>
<td>and guaiac test</td>
<td></td>
</tr>
<tr>
<td>Supine-Erect: blood</td>
<td>Low</td>
</tr>
<tr>
<td>pressure and pulse</td>
<td></td>
</tr>
<tr>
<td>Hematocrit and Hemoglobin</td>
<td>Low</td>
</tr>
<tr>
<td>Proctoscopy and Colonoscy</td>
<td>Low</td>
</tr>
<tr>
<td>Barium Studies</td>
<td>Low</td>
</tr>
<tr>
<td>Angiography</td>
<td>Low</td>
</tr>
</tbody>
</table>

FIG. 1. (A) Time–activity curves demonstrate intermittent nature of lower GI bleeding. Regions over the aorta and bleeding site were used to monitor activity of tandemly administered 99mTc-sulfur colloid (SC) and red blood cells (RBCs). SC is rapidly cleared from the blood pool and none remains to demonstrate the first episode of intermittent bleeding at 26 min postinjection. RBCs re-
main in the vascular space and document the intermittent peaks of active bleeding. (B) Anterior abdominal images at 15, 25, and 40 min (left to right) after injection of 99mTc-RBCs show bleeding site in lower descending colon with bidirectional movement of lumenal ac-
tivity. Diagnosis of a bleeding diverticulum at the site was confirmed at surgery.
ticulae. This study is usually done in children and young adults with lower GI bleeding episodes. A positive study showing concentration of pertechnetate by the ectopic gastric mucosa (Fig. 4) provides strong presumptive evidence that peptic ulceration in the Meckel's is the source of bleeding in the pediatric patient. Overall sensitivity and specificity in 226 reported patients with surgical confirmation of 85% and 95%, respectively, indicates the important continuing role of this study technique (12,13).

Proposed drug and hormone enhancement schemes which might further improve sensitivity are outlined in Table 2.

Active bleeding is not necessary and may actually be detrimental to diagnosing a Meckel's by causing rapid washout of secreted pertechnetate from the lumen. The Meckel's study is best performed as part of the follow-up diagnostic evaluation in patients who have ceased active bleeding. If the patient is actively bleeding, a 99mTc-RBC study should be done to attempt localization of the site.

PATIENT SELECTION

Ideally, scintigraphy should only be performed on patients with a significant amount of lower GI hemorrhage who are bleeding actively at the time of the study.

Patients with an extremely low rate of blood loss will present with chronic anemia and guaiac positive stools. These are not good indications for this study, and such patients are almost invariably negative. They should be studied only as a last resort after negative endoscopy and barium studies have been completed.

In general, 99mTc-RBC scintigraphy should be limited to patients whose bleeding rates make them potential surgical candidates. These patients generally present with hemato-

FIG. 2. Example of tandem 99mTc-sulfur colloid and 99mTc-RBC studies. The SC image at 20 min postinjection is negative. The RBC study became positive in the right upper quadrant at 55 min (middle) and shows progressive bleeding at 80 min (right). Note: Activity in urinary bladder is normal. Angiodysplasia of the ascending colon just below the hepatic flexure was confirmed as the bleeding site.

FIG. 3. Tandem study with sigmoid colon bleeding site demonstrated by both 99mTc-sulfur colloid and 99mTc-RBCs. Anterior view at 15 min following SC administration is on left. Technetium-99m-RBC images at 25 min (middle) and 80 min (right) clearly show the bleeding lesion.

TABLE 2. Hormone/Drug Enhanced Meckel's Study

<table>
<thead>
<tr>
<th>Hormone/Drug</th>
<th>Dose</th>
<th>Desired Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pentagastrin</td>
<td>6 μg/kg</td>
<td>Increased [99mTc]pertechnetate uptake</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>300 mg/day</td>
<td>Block [99mTc]pertechnetate release</td>
</tr>
<tr>
<td>Glucagon</td>
<td>50 μg/kg</td>
<td>Decreased lumen motility</td>
</tr>
</tbody>
</table>

FIG. 4. Anterior view 30 min after i.v. [99mTc]pertechnetate illustrates typical finding of Meckel's diverticulum in the right lower quadrant.
chezia and blood volume changes requiring transfusion. In these patients, the major question concerns when to initiate the study, since it is highly desirable to administer \(^{99m}\text{Tc}-\text{RBC}\) during a bout of active luminal bleeding.

Unfortunately, there are no perfect clinical indications of bleeding activity that can be used to trigger study onset. We reviewed our experience in 1983 and found two clinical factors which helped to select patients most likely to have active bleeding. Orthostatic blood pressure changes were present in 86% of patients with positive scintigraphy and in only 27% of those with negative results (Student's t-test, \(p < 0.01\)). The mean transfusion requirement was 6.9 units packed RBCs in positive cases compared to 1.5 units packed RBCs in negative cases (\(p < 0.001\)). Patients who are bleeding actively by these criteria are studied as soon as possible. They have a higher probability of a positive study during the early sequential imaging phase of the \(^{99m}\text{Tc}-\text{RBC}\) study, when localization of the site is most accurate. Patients without orthostatic changes often have stopped bleeding or are only positive on delay views.

Differences in patient selection criteria may well explain the significant difference in average delay time to a positive study reported by various authors \(4,8,14\). Patient selection criteria are best developed in close coordination with the referring clinicians and probably should be reviewed periodically in the light of study results at a particular institution.

**RBC LABELING CONSIDERATIONS**

Three methods have been utilized to label RBCs with \(^{99m}\text{Tc}\): in vivo method, in vitro method, and the modified in vivo method. All three methods require the addition of a reducing agent, usually stannous ion, to the RBCs prior to adding \([^{99m}\text{Tc}]\text{pertechnetate}\). This process is sometimes called “pre-tinning” the red blood cells. Although \(^{99m}\text{Tc}\) attaches to the beta chain of the hemoglobin molecule, the same location as \(^{51}\text{Cr}\), it requires proper intracellular concentration of the tin reducing agent for labeling to occur.

Other blood-pool radiopharmaceuticals such as \(^{111}\text{In}-\text{RBC}\) and \(^{99m}\text{Tc}-\text{albumin}\) have been used for GI bleeding studies but have not demonstrated any clinical superiority to \(^{99m}\text{Tc}-\text{RBCs}\).

**In Vivo Method**

In this method all circulating RBCs are pre-tinned by i.v. administration of a reconstituted cold pyrophosphate kit containing 1 mg of stannous ion \((15)\). However, when \([^{99m}\text{Tc}]\text{pertechnetate}\) is administered 30 min later, a significant portion remains available for concentration by the salivary glands and gastric mucosa. The subsequent bowel activity often leads to diagnostic confusion, making this method of RBC labeling unacceptable for GI bleeding studies.

**In Vitro Method**

A simple kit to label erythrocytes was developed at the Brookhaven National Laboratory a decade ago \((16,17)\), and it is now available* on an extended IND Phase III unlimited basis for routine clinical use. The in vitro approach provides a consistently superior label for GI bleeding studies because quality control testing and additional washing steps can remove

---

**TABLE 3. Preparation of in Vitro Labeled RBCs**

<table>
<thead>
<tr>
<th>Step</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Add 7 ml of patient whole blood to kit vial which contains: 100 units sodium heparin, 3.7 mg sodium citrate dihydrate, 5.54 mg dextrose anhydrous, 1.5 mg tin as stannous ion NaOH for pH adjustment.</td>
</tr>
<tr>
<td>2.</td>
<td>Centrifuge vial contents at 800 G for 10 min.</td>
</tr>
<tr>
<td>3.</td>
<td>Remove plasma and add 50 mCi ([^{99m}\text{Tc}]\text{pertechnetate}) to the packed cells. Mix and incubate for 10 min.</td>
</tr>
<tr>
<td>4.</td>
<td>Perform quality control to determine percent cellular labeling: Remove 0.5 ml of labeled RBC solution and combine with 1.5 ml normal saline in test tube. Measure total activity in tube, then centrifuge and remove supernatant and count RBC activity. Express as % of total.</td>
</tr>
</tbody>
</table>

*Letterman Army Medical Center Technique \((7)\).

any unbound \(^{99m}\text{Tc}\). This is the ideal tracer and provides consistent image and study quality for bleed localization \(4,18,19\). The steps required for in vitro red cell labeling according to our own modification of the Brookhaven kit are listed in Table 3. This procedure requires ~ 30 min, including the quality control steps.

**Modified In Vivo Method**

This modification of the in vivo technique provides improved labeling efficiency by allowing ~ 10 min incubation of pre-tinned erythrocytes with \([^{99m}\text{Tc}]\text{pertechnetate}\) in the i.v. apparatus \((4,20)\). This is the most commonly used method and is preferred whenever in vitro labeling cannot be done, because it reduces the amount of free pertechnetate interference. This method is outlined in Table 4.

**Special Labeling Problems**

Use of acid citrate-dextrose (ACD) instead of heparin in the modified in vivo labeling technique has been shown to improve binding efficiency and decrease renal and bladder activity related to excretion of \(^{99m}\text{Tc}\)-heparin complexes \((17)\). It is also important to avoid using the initial eluate from long growth-time generators, since \(^{99m}\text{Tc}\) (the decay product of \(^{99}\text{Tc}\)) acts as a competitive inhibitor of eluted \(^{99m}\text{Tc}\) in all types of erythrocyte labeling. The first elution should be discarded and a rapid second elution used whenever the generator ingrowth time is over 24 hr. Patients with low hematocrits seem to require longer incubation times than 10 min for the modified in vivo labeling method. Removal of the incubating syringe for optional centrifugation and washing can be done to assure high labeling efficiency \((22)\).

**IMAGING TECHNIQUES**

The imaging technique utilized for GI bleeding studies is critically important to a successful outcome. The technique must be designed to answer the main clinical question: Where is the bleeding site located? The answer to this question is vital to guiding diagnostic or interventional angiography or for
directing surgical resection of the bleeding bowel segment. Important technique considerations are outlined in Table 5.

### Early Study Technique

A scintigraphic technique must be designed to overcome the localization problems stemming from intermittent lumenal bleeding and bidirectional movement of blood activity in the bowel lumen. This is best accomplished by either continuous dynamic imaging or by using frequent sequential images.

### Delayed Study Technique

When bleeding is not visualized during the early continuous imaging study, delayed images should be obtained at time intervals consistent with clinical requirements. Usually, delayed views may be obtained up to 24 hr with a single 99mTc-RBC dose. If lumenal activity is seen on a delayed view, sequential imaging should be restarted with either the same dose or a lower dose.

#### TABLE 5. Technetium-99m-RBC GI Bleeding Study Techniques

<table>
<thead>
<tr>
<th>Technique</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Study Technique</td>
</tr>
<tr>
<td>LFOV high-resolution system</td>
</tr>
<tr>
<td>Bolus flow study</td>
</tr>
<tr>
<td>Continuous computer imaging</td>
</tr>
<tr>
<td>Individualize early study duration</td>
</tr>
<tr>
<td>Delayed Imaging Options</td>
</tr>
<tr>
<td>Restart sequential imaging</td>
</tr>
<tr>
<td>Initiate new study</td>
</tr>
<tr>
<td>Special Techniques</td>
</tr>
<tr>
<td>Dynamic computer display</td>
</tr>
<tr>
<td>99mTc-DTPA enema</td>
</tr>
<tr>
<td>99mTc-DISHIDA for small bowel anatomy</td>
</tr>
<tr>
<td>Pre- and post-defecation images</td>
</tr>
<tr>
<td>Bedpan image</td>
</tr>
<tr>
<td>Drug interventions</td>
</tr>
<tr>
<td>Ancillary Study Information</td>
</tr>
<tr>
<td>Red cell mass</td>
</tr>
<tr>
<td>LVEF as pre-op screen</td>
</tr>
</tbody>
</table>

Blood in the bowel lumen may move significant distances in both directions within 5–15 min of a bleeding episode. If images are obtained at 20–30-min intervals, there is potential for significant localization error. Imaging should be started at the time of injecting 99mTc-RBCs to assure correct localization of early bleeding. Dynamic flow studies of bolus arrival may prove helpful in identifying certain vascular lesions and artifacts. The highest resolution system should be used to help distinguish bleeding from the vascular background activity, which provides helpful localization landmarks. Studies are conducted best with a large field-of-view camera, but they can be performed with a mobile camera using a diverging collimator.

The duration of the early imaging study should be as long as practically possible until a bleeding episode is visualized. Sequential computer acquisition as a dynamic study for cinematic playback has been extremely useful for localizing intermittent bleeding sites. In a large multi-institutional study (8), 83% of all patients with continued bleeding were visualized during a 90-min computer acquisition (Fig. 5). However, several other series (4,14) report that a majority of patients became positive only several hours after administering 99mTc-RBCs. This difference in timing is probably related to local variation in patient selection and diagnostic workup and emphasizes the need to individualize study duration for a particular institution.

#### FIG. 5. Time-to-positive scintigraphic result of 41 confirmed bleeders. Graph illustrates relationship between detected positive cases and duration of continuous imaging phase of 99mTc-RBC bleeding study. In this series (8), only 17% of confirmed bleeders became positive after 90 min. If the continuous imaging was stopped at 60 min, an additional 8% of the cases would have been missed. Note that even at 20 min, 99mTc-RBCs demonstrated 34% of bleeding sites, whereas 99mTc-sulfur colloid only showed 12%.
new dose of $^{99m}$Tc-RBC in order to confirm the correct location of the bleeding site. This is particularly true when several hours have elapsed between images. Figure 6 is an excellent example of the use of renewed sequential imaging to confirm a bleeding location after delayed views revealed almost pan-colonic distribution of activity (23). Lumenal activity on a delayed view has been dubbed the “nuclear guaiac” test because this merely demonstrates that bleeding has occurred sometime in the imaging interval but does not reliably localize the bleeding site (Fig. 7).

**Special Techniques**

A number of special techniques have been suggested to assist in defining the anatomic bleeding site in those cases where the location is not obvious from activity moving through the bowel lumen.

When it is unclear whether a bleeding site is located in the small bowel or colon, these structures can be outlined scintigraphically by administering either i.v. $^{99m}$Tc-DISHIDA or oral $^{99m}$Tc-sulfur colloid to visualize the small bowel, or a $^{99m}$Tc-DTPA enema for colon visualization (24). These maneuvers should not be attempted until routine images are complete because their interference activity will make it impossible to further evaluate for active bleeding activity (Fig. 8).

When there is confusion between a suspected bleeding site in the sigmoid colon as opposed to the possibility of small bowel or dependent transverse colon, pre- and post-defecation images as well as a bedpan image can provide conclusive sigmoid localization (Fig. 9).

Theoretically, certain drug interventions have the potential to enhance $^{99m}$Tc-RBC bleeding scintigraphy results. Glucagon may be used to slow rapid bowel transit and thus allow increased accumulation of tracer at the bleeding site. Cholecystokinin, on the other hand, can be used to stimulate bowel peristalsis when movement of a bleeding focus might define the location.

Methods designed to stimulate renewed bleeding during sequential imaging must be done with proper medical precautions. Bleeding may be renewed by merely raising the patient’s blood pressure by fluid replacement and pressor agents. Another more risky form of bleeding provocation entails administering heparin (10,000 units by i.v. bolus with 1,000 units i.v. per hr) to patients with chronic oozing (25). This must be
TABLE 6. Technetium-99m-RBC GI Bleed Imaging Artifacts

<table>
<thead>
<tr>
<th>Urine Activity Artifacts</th>
<th>Blood-Pool Activity Artifacts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder artifact</td>
<td>Penile blood flow</td>
</tr>
<tr>
<td>Foley catheter pattern</td>
<td>Mesenteric varices</td>
</tr>
<tr>
<td>Renal outflow dilation/obstruction</td>
<td>Aneurysm or AVM</td>
</tr>
<tr>
<td></td>
<td>Uterus blood pool</td>
</tr>
<tr>
<td></td>
<td>Tumor blood pool</td>
</tr>
</tbody>
</table>

done under careful monitoring in order to immediately reverse the anticoagulant effect when bleeding is seen.

Ancillary information such as calculation of red cell mass and left ventricular ejection fraction is readily available from the same dose of $^{99m}$Tc-RBC. This type of information could be helpful in monitoring transfusion requirements and could be used for pre-operative cardiac screening.

INTERPRETATION PITFALLS

Normal variations and common artifacts that can be confused with bleeding sites are listed in Table 6. Each of these structures has identifiable characteristics. Vascular lesions will show no change in location or relative intensity over time (Fig. 10). Artifacts caused by urinary excretion are readily identified in most cases. Confusion between recto-sigmoid bleeding and urinary bladder activity can usually be resolved by pre- and post-defecation views, and penile activity can be identified by moving the penis and re-imaging.

SUMMARY

Scintigraphic detection using $^{99m}$Tc-RBCs is now commonly accepted as the best initial diagnostic test in patients with lower GI hemorrhage. With proper patient selection, attention to technical details, and avoidance of potential pitfalls, this study has provided diagnostic sensitivity, specificity, and overall accuracy in the mid-90% range at a number of institutions (8). Since this test is often pivotal in surgical or interventional decisions, it should be available on an emergency basis.

ACKNOWLEDGMENT

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.

FOOTNOTE

*Cadema Medical Products, Inc., Middletown, NY
REFERENCES


